1YI0 Stock Chart & Stats
€0.28
€0.00(0.00%)
At close: 4:00 PM EDT
€0.28
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.38
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.34M
Enterprise Value-€4.20
Total Cash (Recent Filing)€6.43M
Total Debt (Recent Filing)€184.00K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 13, 2026EPS Estimate
-2.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9933.94
Shares Outstanding1,620,861
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.71Price Target Upside5154.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated CAPTN-3 Platform (IM1240) Preclinical ValidationRobust preclinical safety and tumor‑remodeling data for IM1240 support a durable technical advantage: the masked tri‑specific design addresses core safety limitations of T‑cell engagers, improving exposure and therapeutic window which enhances long‑term partnerability and clinical translation odds.
Clear Strategic Focus And External CollaborationsConcentrating resources on CAPTN‑3, adding a scientific advisory board and expanding an AI discovery partnership signal stronger governance and focus. This increases development efficiency, improves program prioritization, and raises the chance of productive partnerships or licensing that sustainably de‑risks the pipeline over months.
Conservative Balance Sheet With Low LeverageVery low debt reduces fixed financial obligations and interest risk, giving management flexibility to pursue non‑debt financing, partnerships or staged R&D spending. Over a multi‑month horizon this conservatism lowers bankruptcy probability and supports strategic options to fund clinical milestones.
Bears Say
Limited Cash Runway Into Mid‑2027A runway only into mid‑2027 creates an imminent financing cliff ahead of planned Phase 1 activity. The company must secure partnering, milestone payments, or capital within months; failure or dilutive financing would materially affect ability to reach clinical inflection points and long‑term strategy execution.
Effectively No Revenue And Sustained LossesAbsence of operating revenue forces reliance on external funding and partnership deals. Persistent multi‑year losses have eroded equity, increasing vulnerability to funding squeezes and raising the likelihood of dilution or asset sales to sustain development over the medium term.
Platform Remains Preclinical Until 2027 Clinic EntryDespite promising preclinical data, IM1240’s value is contingent on successful clinical translation. Preclinical validation does not guarantee human safety or efficacy; until Phase 1/2 readouts materialize, commercial potential and partner interest remain speculative, raising execution and regulatory risk.
Purple Biotech News
1YI0 FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was €0.28 and its highest was €0.38 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is €9.34M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Nov 13, 2026 which is in 94 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Aug 07, 2026. The company reported €0.303 earnings per share for the quarter, the consensus estimate of €0.303 by €0.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -2.49.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,620,861 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of €0.303 in its last earnings report, expectations of €0.303. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in DE:1YI0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
1YI0 Stock 12 Month Forecast
Average Price Target
€14.71
▲(5154.58% Upside)